The Alpha Mannosidosis by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Alpha Mannosidosis Market:
https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report
According to The Business Research Company’s Alpha Mannosidosis, The alpha mannosidosis market size has grown rapidly in recent years. It will grow from $12.77 billion in 2023 to $15.26 billion in 2024 at a compound annual growth rate (CAGR) of 19.5%. The growth in the historic period can be attributed to emerging market growth, urbanization, increased demand for man-made fibers and government initiatives for the textile industry.
The alpha mannosidosis market size is expected to see rapid growth in the next few years. It will grow to $29.62 billion in 2028 at a compound annual growth rate (CAGR) of 18.0%. The growth in the forecast period can be attributed to global population growth and urbanization, increasing e-commerce, increasing demand for sportwear, increasing penetration of organized retail in developing economies and increasing penetration of social media. Major trends in the forecast period include increasing use of enzyme therapy, adopting the use of hematopoietic stem cell transplantation, and adopting the use of cisterna magna infusion.
Rising regulatory support for the drug approval of rare diseases in alpha mannosidosis is expected to drive the market in the forecast period. The inherently small population of patients with a rare disease can also make conducting clinical trials difficult. But to tackle this, in 2021, the FDA announced providing support for the development and evaluation of new treatments for rare diseases making it a key priority. The FDA has the authority to grant orphan-drug designation to a drug or biological product to prevent, diagnose, or treat a rare disease or condition. Orphan drug designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval. Thus, the rising support for regulatory bodies will propel the market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=4093&type=smp
The alpha mannosidosis market covered in this report is segmented –
1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Other Therapies
2) By Indication: Type I, Type II, Type III
3) By End-User: Hospitals, Speciality Clinics
Major companies operating in the alpha mannosidosis market are focusing on developing enzyme replacement therapy for rare alpha-mannosidosis. By supplying exogenous alpha-mannosidase, enzyme replacement therapy helps reduce the accumulation of mannose-rich oligosaccharides in various tissues and organs. This accumulation is a characteristic feature of alpha-mannosidosis and contributes to the disease’s pathological effects. For instance, in February 2023, Chiesi Global Rare Diseases a US-based pharmaceutical company launched Lamzede (velmanase alfa), the first enzyme replacement therapy authorized in the United States for the treatment of alpha-mannosidosis, a rare genetic condition marked by an absence of the enzyme alpha-mannosidase in the body, and its manifestations outside of the central nervous system. Lamzede restores normal cellular activity in patients by acting in the same manner as the human body’s alpha-mannosidase enzyme. Once a week, patients receive an injection of 10 mg of Lamzede.
The alpha mannosidosis market report table of contents includes:
1. Executive Summary
2. Alpha Mannosidosis Market Characteristics
3. Alpha Mannosidosis Market Trends And Strategies
4. Alpha Mannosidosis Market – Macro Economic Scenario
5. Global Alpha Mannosidosis Market Size and Growth
.
.
.
26. South America Alpha Mannosidosis Market
27. Brazil Alpha Mannosidosis Market
28. Middle East Alpha Mannosidosis Market
29. Africa Alpha Mannosidosis Market
30. Alpha Mannosidosis Market Competitive Landscape And Company Profiles
Top Major Players:
- Chiesi Farmaceutici S.p.A
- Cipla
- EdiGene Inc
- Immunochina
- Takara Bio
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
